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Determination of Monoamine Oxidase A and B Activity in
Long-Term Treated Patients With Parkinson Disease
Thomas Müller, MD, PhD,* Peter Riederer, PhD,† and Edna Grünblatt, PhD‡§||
Background: Biogenic amines and monoamine oxidase inhibitors influ-
ence peripheral monoamine oxidase enzyme activity in chronic levodopa/
dopa decarboxylase inhibitor–treated patients with Parkinson disease.
Rasagiline is an irreversible inhibitor of monoamine oxidase B. Safinamide
blocks this isoenzyme in a reversible fashion.
Objectives: The aim of this study was to determine monoamine oxidase
A (plasma) and B (platelets) enzyme activity in long-term levodopa-treated
patients without and with additional oral intake of 50- or 100-mg safinamide
or 1-mg rasagiline or first-time intake of rasagiline.
Results:Monoamine oxidase A enzyme activity did not differ between all
groups. Patients on rasagiline or safinamide showed lower monoamine
oxidase–B enzyme activity compared with patients without monoamine
oxidase B inhibitor intake. No impact of the number of previous oral levo-
dopa intakes was found.
Discussion: Rasagiline and safinamide did not essentially differ in terms
of inhibition ofmonoamine oxidase B despite their different pharmacology
regarding reversibility of monoamine oxidase B inhibition. In view of the
observed, considerable heterogeneity of enzyme activities, we suggest to
determine activities of monoamine oxidase A and B to reduce the risk
for tyramine-induced hypertension and the serotonergic syndrome during
chronic therapy with rasagiline or safinamide.
Key Words: monoamine oxidase, safinamide, rasagiline
(Clin Neuropharm 2017;00: 00–00)
M onoamine oxidase (MAO; EC 1.4.3.4) is essential for degra-dation of biogenic amines in neuronal and glial cells of the
brain. Inhibition of MAO provides higher and more sustained
levels of biogenic amines concentrations in the synaptic cleft.
TwoMAO enzyme forms exist, the A and B isoforms. Monoamine
oxidases A and B differ in the anatomical localization and prefer-
ence of substrates. Monoamine oxidase A is primarily found in
the placenta, gut, and liver and degrades serotonin and noradrena-
line. Monoamine oxidase B predominantly appears in the brain,
liver, and platelets, and phenylethylamine, methylhistamine, and
tryptamine are its primary substrates.1 Both, MAO-A and MAO-B,
metabolize tyramine and dopamine. Inhibition of one MAO isoform
activity only is enabled within a certain and rather low concentration
range of the administered compound. The specificity of a certain
MAO subtype inhibition vanes with higher and chronic dosing of
the applied drug, which results in an unselective blocking of both
MAO-A and MAO-B.2,3 Reversible and irreversible MAO-B inhibi-
tion is a well-accepted and proven therapeutic principle for patients
with Parkinson disease (PD). Currently, there are 2 irreversible
MAO-B inhibitors, selegiline and rasagiline, available. Safinamide
is a further one, but this compound inhibits MAO-B in a reversible
fashion.4,5 Generally, the concentration of the substrate essentially de-
termines enzyme activity. In case of drug-induced blocking of MAO,
the substrate, that is, the biogenic amine dopamine, and the dosing of
the MAO inhibitor influence the enzyme activity of MAO.6 In other
words, in levodopa/dopa-decarboxylase inhibitor (DDI)–treated pa-
tients, peripheral dopamine levels and the MAO inhibitor itself may
influence the MAO enzyme activity in the periphery.7 In this respect,
one must consider that inhibition of dopa-decarboxylase with
carbidopa or benserazide does not totally prevent the peripheral
decarboxylation of levodopa to dopamine.7,8 In a previous trial,
we described a decline of MAO-A enzyme activity when expos-
ing it to plasma taken from patients with PD, who were on a
long-term therapy with irreversible MAO-B inhibitors with and
without levodopa/DDI.2 However, this trial examined patients
with PD without consideration of the number of additional previ-
ous oral levodopa/DDI intakes, when blood sampling was per-
formed 4 hours after the intake of the MAO-B inhibitor.7 The
objective of the present investigation was to measure MAO-A
(plasma) and MAO-B (platelets) activity in chronic levodopa-
treated patients with PDwith and without rasagiline or safinamide
therapy and in relation to previous levodopa intake.
METHODS
Subjects
Exclusion criteria were metabolic disturbances, namely, dia-
betes; abnormal vitamin values (ie, B6, B12, folic acid); clinical
signs of dementia; or any electrophysiological or morphological
evidence (cranial computed tomography or magnetic resonance
imaging scan) of additional central nervous system pathology ex-
ceeding PD. We investigated 7 cohorts of levodopa/DDI-treated
patients. Cohort 1 was rasagiline-treated patients with PD, cohort
2 took safinamide on a regular basis (for characteristics, see
Table 1). Patients of cohort II were additionally subgrouped and
analyzed according to their intake of the safinamide dosage
(safinamide 50 mg in cohort III, safinamide 100 mg in cohort
IV). Patients with PD without any previous MAO-B inhibitor
intake and oral levodopa intake on the investigation day were in
cohort V. Cohort VI included patients who took rasagiline for
the first time in their life, and blood sampling was performed ap-
proximately 4 hours after rasagiline intake with concomitant
levodopa/DDI application.
Assessment of MAO-A and MAO-B Activity
Determination of MAO-A was performed with plasma as
described previously2 with several modifications. Monoamine
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oxidase B assessment was performed in platelets.9 Total protein
in plasma and platelets was assessed using the Bradford assay.
Both MAO-A and MAO-B activity assay was conducted using
the MAO-Glo Assay (Promega, Germany). For the MAO-A
activity assay, the recombinant human MAO-A enzymewas used
(Sigma-Aldrich). Luciferase was detected in black 96-well plates
(Thermo-Fisher Scientific, Switzerland) on the Mithra2 LB 943
Multimode Reader (Berthold Technologies, Germany).
Design
According to Table 1, blood sampling was performed before
levodopa intake (ie, cohort V) or after levodopa intake (ie, cohorts
I, II, III, IV, and VI). The additional concomitant drug therapy was
not changed. We did not aim to evaluate the motor response on
the additional application of the MAO-B inhibitor.
Statistics
Values of all groups passed the Shapiro-Wilk normality test.
ANOVAwas used for the comparisons. The Tukey multiple com-
parison test was used for the post hoc analysis. P value of 0.05
was regarded as significant. Because (1) we split patients of
cohort II into cohorts III and IVand (2) gastrointestinal levodopa
absorption and peripheral turnover of levodopa to dopamine by
dopa decarboxylase are heterogeneous,8,10,11 we did not perform
a covariate analysis in this descriptive, explorative analysis of this
pilot investigation.
Ethics
All subjects gave written informed consent. An independent
local institutional review board approved the additional blood col-
lection. This investigation was advertised according § 4 Abs. 23
Satz 3 AMG at the medical association. It was characterized as
noninterventional and thus observational because blood sampling
is part of the routine surveillance in the treatment for patients
with PD.
RESULTS
MAO-A Activity
There were no significant differences between all cohorts
(F5,71 = 1.07, P = 0.38) (Fig. 1).
MAO-B Activity
MAO-B activity (F5,71 = 20.25, P < 0.001) varied between
groups. The post hoc analysis showed that there is no difference be-
tween safinamide and rasagiline in terms of MAO-B inhibition
(Fig. 2). There was a significant difference between rasagiline
long-term treated patients and the ones without previous MAO-B
inhibitor intake and patients 4 hours after first-time intake of
rasagiline (Fig. 2). Similar outcomes were obtained in terms of
safinamide; again, significant differences of MAO-B activity ap-
pearedwhen comparedwith the values of patients without previous
MAO-B inhibitor intake and patients 4 hours after first-time intake
of rasagiline (Fig. 2). Application of safinamide during long-term
use did not result in a more pronounced inhibition of
MAO-B (Fig. 2). Both relative small safinamide dosing sub-
groups had a lower MAO-B activity than patients with PD
without MAO-B inhibitor intake (Fig. 2), but the 50-mg
safinamide dose did not differ from patients with first-time
rasagiline intake in contrast to safinamide 100-mg group
(Fig. 2). No significant difference was found between patients
without previous levodopa and MAO-B inhibitor intake andTA
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patients with previous levodopa and first-time MAO-B inhibi-
tor intake (Fig. 2).
DISCUSSION
We show that both, rasagiline and safinamide, does not affect
“ex vivo” determined MAO-A enzyme activity. We found no im-
pact of the number of levodopa/DDI intakes on the investigation
day onMAO-A activity.7 In viewof our present results, we assume
that the previous hypothesis of MAO-A inhibition by rasagiline,
respectively selegiline, during long-term application according
to the outcomes of an earlier trial warrants further experiments
particularly in healthy and age-matched controls. In that earlier in-
vestigation, we indirectly measured MAO-A enzyme activity in a
similar fashion as in this study and found a reducedMAO-A activ-
ity in comparisonwith the controls.2 To date, we cannot exclude in
both trials that the applied MAO activity influencing drugs was
not fully metabolized and excreted, when the plasma sample was
taken.7 Thus, during chronic application, accumulation of the
compound may also exhibit a certain effect on MAO-A in the
FIGURE 1. Scatterplot of MAO-A activity in the various cohorts. All cohorts showed lower enzyme values than the controls (P < 0.001
according to the post hoc analysis). Cohorts: RAS, daily 1-mg rasagiline; SAF, daily safinamide; SAF 50, daily 50-mg safinamide; SAF 100,
daily safinamide 100 mg; no MAO-B_I, no previous MAO-B inhibitor intake and oral levodopa intake; 1st RAS, rasagiline for the first time in
their life and blood samplingwas performed approximately 4 hours after rasagiline applicationwith concomitant levodopa/DDI application.
RLU indicates relative light unit.
FIGURE2. Scatterplot ofMAO-B activity in the various cohorts. Cohorts: RAS, daily 1-mg rasagiline; SAF, daily safinamide; SAF 50, daily 50-mg
safinamide; SAF 100, daily safinamide 100mg; noMAO-B, no previousMAO-B inhibitor intake and oral levodopa intake; 1st RAS, rasagiline
for the first time in their life and blood sampling was performed approximately 4 hours after rasagiline application with concomitant
levodopa/DDI application. RLU indicates relative light unit.
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applied in vitro experiment for the indirect measurement of
MAO-A.2,9 Another hypothesis would be that elevation of periph-
eral dopamine generation by levodopa application and synthesis
of other biogenic amines resulting from chronic DDI administration
may also generate an effect on MAO enzyme activity in general.12
This could contribute to the observed scattering of MAO-A and
MAO-B enzyme activity in all cohorts. A further complementing
reason may particularly be an elevated generation of dopamine,
which is anMAO substrate and thus inhibitsMAO enzyme activity.
The concomitant intake of levodopa with a DDI does not prevent
that a considerable amount of levodopa still undergoes peripheral
decarboxylation to dopamine.12 Thus, the individual variability of
levodopa plasma bioavailability after gastrointestinal levodopa ab-
sorption may also contribute to the observed variation of peripheral
MAO enzyme activity.11 Here, we found no impact of previous
levodopa intake on MAO-A enzyme activity and cannot postulate
such an effect in the case of MAO-B because of the missing control
group in contrast to our earlier trial.2 A further theoretical cause
may be that this phenomenon additionally at least partially results
from the presence of endogenous MAO inhibitors.13
Rasagiline and safinamide are both MAO-B inhibitors. Both
drugs in the applied dosages do not essentially differ in reducing
of MAO-B activity, despite their different pharmacological
properties in terms of reversibility of MAO-B blocking. The more
pronounced reduction of MAO-B activity after repeated MAO-B
inhibitor intake compared with first-time administration of
rasagiline may hypothetically result from a certain cumulative ef-
fect generated by the MAO-B inhibitor on MAO-B enzyme activ-
ity or on MAO-B synthesis. There was no difference of MAO-B
activity between cohorts III and VI, but the number of patients
on a 50-mg safinamide regimen is rather low. Therefore, we
refrain from claiming that the effects of chronic 50-mg safinamide
intake on MAO-B enzyme activity correspond to the one of first-
time dosing of 1-mg rasagiline.
We demonstrate heterogeneity of the extent ofMAO inhibition
by rasagiline and safinamide in Figures 1 and 2. Generally, there is a
discussion on the so-called “cheese” effect during MAO inhibition.
In view of the observed peripheral variability of MAO inhibition,
we suggest that only individuals with a pronounced MAO inhibi-
tion are at risk to develop this tyramine-induced hypertension dur-
ing MAO inhibition. Therefore, assessment of MAO-A and
MAO-B activity during MAO inhibition may hypothetically help
to identify these “cheese effect at risk” individuals and allow to rec-
ommend them preventive dietary restrictions. We also recommend
these assessments particularly during combination of serotonin re-
uptake inhibitors with MAO-B inhibitors. This may reduce the risk
for onset of a serotonergic syndrome. Moreover, the observed het-
erogeneous enzyme activity suggests that fixed dosing of MAO-B
inhibitors should not be recommended in clinical practice. We sug-
gest that it would be better to titrate and apply MAO-B inhibitors in
various dosages to achieve the optimum motor response in relation
to levodopa dosing. In this regard, assessment of enzyme activity
may be advantageous.
Limitations of this present pilot investigation are the relatively
small number of subjects in some cohorts; the absent comparison
with healthy, age-matched controls; the missing determination of
peripheral levodopa and dopamine concentrations; and the hetero-
geneity of levodopa dosing—respective moments of levodopa dos-
ing. Therefore, these outcomes should be regarded as preliminary.
Nevertheless, these results provide some deeper insight in the
complexity of drug-induced regulation of enzyme activity in
chronic treated patients with PD. This kind of research warrants
further studies to investigate the effects of short- and long-term
levodopa treatment on MAO inhibition. To date, certain long-
term effects, such as induction of enzyme generation, during
chronic levodopa/DDI supplementation are not well investigated.
In conclusion, we show with this observational pilot investi-
gation that rasagiline and safinamide presumably inhibit MAO-B
but not MAO-A.
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